Metalla Royalty & Streaming Ltd.

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

2026-07-27 06:00:00

IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the 7 major cytochrome P450s IDE892 Phase 1/2 escalation has cleared multiple dose cohorts and projected efficacious target exposures have been achieved to initiate the Part 2 monotherapy expansion. The IDE892 escalation is ongoing in parallel and the MTD has not yet been reached  IDE892 and IDE397 combination escalation are ongoing in MTAP NSCLC and PDAC, and IDE892 and pan-RAS combination FPI in MTAP PDAC is targeted for H2 2026 MTAP-deletion is estimated to occur in up to 40% of PDAC and ~15% of NSCLC IDEAYA is targeting a MTAP/CDKN2A, KRAS, and Pancreatic Cancer R&D Day in Q4 2026.

METALLA ANNOUNCES VOTING RESULTS FROM ANNUAL GENERAL MEETING AND INVESTMENT FROM SANDEEP SINGH

2026-06-23 16:30:00

TSXV: MTA NYSE AMERICAN: MTA VANCOUVER, BC, June 23, 2026 /PRNewswire/ - Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") (NYSE American: MTA) (TSXV: MTA) is pleased to announce the voting results for its annual general meeting of shareholders held on June 23, 2026 (the "Meeting") where all director nominations and other items recommended by the board of directors of the Company (the "Board") were approved.

METALLA PUBLISHES 2026 ASSET HANDBOOK AND ANNUAL LETTER TO SHAREHOLDERS

2026-06-23 07:00:00

TSXV: MTA NYSE AMERICAN:  MTA VANCOUVER, BC, June 23, 2026 /PRNewswire/ - Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") (NYSE American: MTA) (TSXV: MTA) is pleased to announce the release of its 2026 Asset Handbook outlining the Company's high-quality gold, silver, and copper production, development, and exploration assets, as well as Mineral Reserve and Mineral Resource data.

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

2026-06-15 06:00:00

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhibition of any of the 7 major cytochrome P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4) based on full kinetic CYP inactivation assays IDE892 monotherapy Phase 1 escalation has cleared multiple dose cohorts with maximally efficacious target exposures anticipated at a favorable pill size and the MTD has not yet been reached. IDE892 monotherapy expansion is anticipated in Q3 2026 MTAP-deletion is estimated to occur in up to 40% of pancreatic cancer and ~15% of non-small cell lung cancer (NSCLC) SOUTH SAN FRANCISCO, Calif.

METALLA ANNOUNCES NOMINATION OF SANDEEP SINGH TO THE BOARD IN CONNECTION WITH ITS UPCOMING AGM

2026-05-15 08:00:00

METALLA ANNOUNCES NOMINATION OF SANDEEP SINGH TO THE BOARD IN CONNECTION WITH ITS UPCOMING AGM PR Newswire VANCO

METALLA ANNOUNCES NOMINATION OF SANDEEP SINGH TO THE BOARD IN CONNECTION WITH ITS UPCOMING AGM

2026-05-15 07:30:00

TSXV: MTA NYSE AMERICAN: MTA VANCOUVER, BC, May 15, 2026 /PRNewswire/ - Metalla Royalty & Streaming Ltd. ("Metalla") or ("Company") (NYSE American: MTA) (TSXV: MTA) is pleased to announce that the Company has nominated Mr.

METALLA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND PROVIDES ASSET UPDATES

2026-05-14 16:30:00

(All dollar amounts are in thousands of United States dollars unless otherwise indicated, except for shares, per ounce, and per share amounts) TSXV: MTA NYSE American: MTA VANCOUVER, BC, May 14, 2026 /PRNewswire/ - Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") (TSXV: MTA) (NYSE American: MTA) announces its operating and financial results for the three months ended March 31, 2026.

Hybrid Power Solutions Receives First Purchase Order from MTA New York City Transit

2026-05-05 08:01:00

Inaugural sale for Batt Pack Spark portable power system with MTA New York for Approximately C$80,000 TORONTO, Ontario – TheNewswire - May 5, 2026 – Hybrid Power Solutions Inc. (CSE: HPSS) (OTC: HPSIF) (FSE: E092) (“Hybrid” or the “Company”), an emerging leader in the delivery of fuel-free clean power solutions, is pleased to announce it has received a purchase order from Metropolitan Transportation Authority (MTA) New York City Transit for one Batt Pack Spark (30kWh) portable power system together with four Folding Solar Panels (500W). The total value of the contract is expected to be approximately C$80,000, with delivery scheduled for the Company's Q1 2027 (fiscal quarter ending August 2026, due to the Company's May fiscal year-end).